The Committee for Medicinal Products for Human Use (CHMP) recommended 2 insulin biosimilars for marketing authorization in Europe.
Europe’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for 2 insulin biosimilars, meaning that the agency has recommended the European Commission (EC) grant them marketing authorization.
The opinions are in reference to Inpremzia, a human insulin biosimilar referencing Actrapid, and Truvelog Mix 30, an insulin aspart biosimilar referencing NovoMix 30. The 2 products mark the fifth and sixth approvals for insulin biosimilars for use in the European Union.
More on Truvelog Mix 30
Truvelog Mix 30 was developed by Sanofi-Aventis and is an extension of the original Truvelog (100 U/mL), which was approved for marketing in Europe in June 2020 and references NovoRapid, also known as Novolog in the United States. NovoMix is a Novolog product that contains 30% insulin aspart, an intermediate- or long-acting insulin, and 70% insulin aspart protamine, a fast-acting insulin.
It takes less than 30 minutes to activate once injected, and the peak action is reached in the first 1 to 4 hours and lasts for less than 24 hours. In some countries, NovoMix 30 is marketed as Novolog Mix. A similar product developed by Mylan IRE Healthcare Limited (Kirsty; formerly known as Kixelle) was approved for marketing authorization in the European Union in February 2021.
If granted marketing authorization from the EC, the substance will be available as a 100-U/mL suspension for injection and is indicated for use in adults, adolescents, and children 10 years or older with type 2 diabetes.
The original Truvelog was also approved by the Australian Therapeutic Goods Administration, the Australian equivalent of the FDA and the European Medicines Agency, in October 2020.
More on Inpremzia
Inpremzia was developed by Baxter Holding and is indicated for the treatment of patients with type 2 diabetes. The biosimilar will be available at a 1-IU/mL solution for infusion. Inpremzia is a fast-acting injectable insulin that lowers blood glucose by allowing for glucose to be absorbed into muscle and fat cells, inhibiting glucose output from the liver.
The originator, Actrapid, was approved for use in the European Union in October 2002. The CHMP based its positive opinion on data comparing Actrapid to Inpremzia that demonstrated similar safety and efficacy profiles between the 2 products. Neutral insulin injections like Actrapid and Inpremzia begin lowering the patient’s blood sugar level about 30 minutes after administration and lasts for approximately 8 hours.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.